###
中国临床研究英文版:2026,39(8):1141-1146
View/Add Comment     过刊浏览    高级检索     
←前一篇   |   后一篇→
本文二维码信息
码上扫一扫!
环状RNA工程化肿瘤免疫治疗进展
(1. 广东医科大学中美肿瘤研究所, 广东 东莞 523808;2. 茂名市人民医院肿瘤科三区, 广东 茂名 525000;3. 广东新安职业技术学院医药健康学院, 广东 深圳 518052)
Advances in engineered circular RNA-based cancer immunotherapy
摘要
本文已被:浏览 314次   下载 320次
Received:April 14, 2026   Published Online:August 25, 2026
中文摘要: 环状RNA(circRNA)因其共价闭合结构,具有较强的核酸酶抗性和体内稳定性,在肿瘤免疫治疗中展现出重要转化潜力。相比信使RNA(mRNA)疫苗,circRNA无需5′端帽和poly(A)尾即可实现高效、持久的抗原表达,且免疫原性较低。本文综述了circRNA通过调控T细胞功能、巨噬细胞极化及免疫检查点表达参与肿瘤免疫微环境重塑的作用,总结了其体外合成与递送技术进展,并分析了circRNA 与微小RNA(miRNA)共载的应用前景。尽管其在规模化生产、靶向递送、免疫原性控制及长期安全性评估方面仍面临挑战,但随着环化与递送技术持续优化,circRNA有望为个体化肿瘤免疫治疗带来新的突破。
Abstract:Circular RNAs(circRNAs),defined by their covalently closed backbone,exhibit exceptional resistance to exonuclease digestion and enhanced in vivo stability,underscoring their considerable promise for clinical translation in cancer immunotherapy. In contrast to messenger RNA(mRNA)vaccines,circRNAs enable efficient and sustained antigen expression independent of a 5′cap or poly(A)tail,while displaying lower immunogenicity. This review systematically summarizes the regulatory roles of circRNAs in reshaping the tumor immune microenvironment via modulation of T cell function,macrophage polarization,and immune checkpoint expression. Furthermore, recent progress in in vitro circRNA synthesis and delivery strategies is outlined,and the therapeutic potential of circRNA - microRNA(miRNA)co - delivery is discussed. Despite persistent challenges—including large - scale production,targeted delivery,control of immunogenicity,and long-term safety evaluation — ongoing advances in circularization efficiency and delivery systems are expected to facilitate the application of circRNAs in personalized cancer immunotherapy.
文章编号:     中图分类号:R730.51    文献标志码:A
基金项目:国家自然科学基金面上项目(81372137);广东省自然科学基金(2022A1515011655);茂名市直医疗卫生机构科技计划专项(2024kjcxLX003)
引用文本:


Scan with WeChat

Scan with WeChat